NDAORALTABLET
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
6/8 — Strong
TRULANCE (plecanatide) by Salix Pharmaceuticals is guanylate cyclase activators [moa]. Approved for chronic idiopathic constipation, irritable bowel syndrome with constipation, functional constipation. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRULANCE (plecanatide) is an oral guanylate cyclase-C agonist approved by the FDA in January 2017 for chronic idiopathic constipation. The drug activates guanylate cyclase-C receptors in the intestinal epithelium, increasing intracellular cGMP levels to enhance fluid secretion and promote bowel movements. It represents a novel mechanism of action in the constipation treatment landscape, distinct from osmotic laxatives and stool softeners.
$0.1BPart D
8.1 years to LOEMechanism of Action
Guanylate Cyclase Activators
Pharmacologic Class:
Guanylate Cyclase-C Agonist
Worked on TRULANCE at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.